After the GLP-1, where is the next breakthrough in weight-loss drugs?
With global GLP-1 drug sales exceeding $50B in 2024, the weight-loss drug market is evolving fast — but the future goes far beyond single-target therapies.
From GLP-1 multi-target combinations to emerging mechanisms like amylin, ACSL5, and ActRII, the next generation of treatments is shifting toward metabolic optimization, muscle preservation, and sustainable weight loss.
2025-06-19